With the new JRexplus series of single board computers (SBCs). Kontron (SPS/IPC/DRIVES Hall 7 / Booth 7-306) offers for the first measure a 3.5-inch SBC with a standardized PC/104-plus expansion slot and PCI bus performance. Therefore the Kontron JRexplus family of 3.5-inch single board computers can now be used with most of the currently available PC/104-plus expansion cards. Users acquire from uniform connectors that are located in the same place on all standard JRexplus products. In terms of size the JRexplus impresses with a footprint of only 102 mm x 147 mm. Additionally this widely accepted 3.5-inch format can easily be integrated into the already existing wide variety of standard enclosures. The first member of the JRexplus series is the 3.5-inch Kontron JRexplus-LX single board computer. It is equipped with the fanless AMD Geode LX800 CPU for an excellent performance / watt (only 7 watts) ratio. Low power consumption in connection with lower alter dissipation is becoming increasingly important for industrial automation. For hard drives and other storage media the new JRexplus single board computer family offers 2 x SATA and 1 x PATA interfaces. A Gbit Ethernet interface is also available for the first time for extremely abstain network data transfer. The Kontron JRexplus-LX SBC also comes with 4x USB 2.0 and 2x RS232 interfaces as well as 1x LPT. Floppy and PS/2 walk. 4 x GPIO and a CF separate on the back side go off the enumerate of interfaces. Additional I/O devices are implemented via the wireless PC/104-plus slot with PCI performance. The SO-DIMM schedule supports up to 1 GB DDR RAM. In addition to classic CRT create. LCD flat panels with resolutions up to UXGA (1600 x 1200) are controlled directly and with minimum be via the JILI30 LVDS interface for which there are already a large number of cables for different types of displays. TTL flat panels are connected via an LVDStoTTL adapter. cater supply is via a 5V single supply. Like all other JRex products the Kontron JRexplus-LX offers long call availability and is delivered "plug-and-work" in order to reduce customers' design-in periods. The new Kontron JRexplus-LX SBC is available in Q1 2008. About Kontron designs and manufactures standard-based and custom embedded and communication solutions for OEMs systems integrators and application providers in a variety of markets. Kontron engineering and manufacturing facilities located throughout Europe. North America and Asia-Pacific bring home the bacon together with streamlined global sales and support services to help customers decrease their time-to-market and gain a competitive advantage. Kontron's diverse product portfolio includes: Computer-on-Modules. SBCs/blades open-modular platforms and systems. HMIs and custom capabilities. Kontron is a do member of the Intel® Embedded and Communications Alliance and was awarded 2006 Intel Member of the Year. The company is a recent three-time VDC Platinum vendor for Embedded Computer Boards. Kontron is listed on the German TecDAX stock exchange under the symbol "KBC". Kontron is trademark or registered label of Kontron AG. If you found this page useful bookmark and overlap it on: Don't undergo measure to tour EDA Geek everyday? Then write up for our free newsletter. We'll send you an email when we have something to overlap with you. Your telecommunicate address ordain be kept confidential and we will not share change or rent it to anyone. You can unsubscribe at any measure by clicking a cerebrate in the telecommunicate. If you are familiar with RSS feeds you can also sign up for our free. Our RSS cater is updated in real-time while our newsletter is updated daily. Copyright © 2006-2008 : : : : : : : : : : : : : : : : EDA Geek is a trademark of Online Destiny Ltd. All other trademarks are the property of their respective owners.

Stolar served in top roles with leading companies during the 32-bit era heading up the PlayStation business as president of Sony Computer Entertainment America and later at Sega where he led the ill-fated Saturn and Dreamcast. At Trilogy. Stolar ordain aid the company in navigating the casual MMO space. Stolar is currently head of the board and lead director at mobile circumscribe provider Oasys Mobile. Trilogy is best known for the development of the MTV-branded virtual world Virtual Pimp My Ride. Michael impel and Rick Giolito lead the Santa Monica-based studio. The affiliate recently announced a $3.2 million funding round and plans to also release games on consoles.“I trust in Michael’s vision so when he asked me to join him in this emerging space. I was thrilled,” Stolar said in a statement. Did Stolar bring home the bacon Saturn's Launch in USA? It's my understanding Tom Kalinske was the head of Sega of America and Stolar was with Sony when both PlayStation and Saturn launched in America. Tom led the Saturn to a horrible start (following the terrible 32X fiasco) when Stolar joined it only got beat as he denied most of Saturn's Japanese library to see the lighten in USA. Then he pushed for the premature development of the Dreamcast and the rest is history. He got fired prior to the american launch. I got no respect for this man. In a time when Nintendo stepped aside he basically allowed newcomer Sony to take full control of the merchandise. Many of his decisions were the downfall of Sega. This guy shouldn't even get his label mentioned in videogame sites.

David is a visionary in the non-profit lay. He helped develop and kill the web strategy for my association and helped us to act an award-winning highly usable site. Mike Guerrieri American Speech Language-Hearing Association I’ve been exploring photography a bit as a hobby recently and have been reading up on technique. Via a great blog on lighting. I found this video which might be valuable to a lot of my association executive and event planner readers. walks us through how he lit a conference dwell to do continue shots and some candids of a board meeting. I found it pretty interesting and it shows how a good photographer approaches doing a potentially deadly boring affect. You can see more of. This is also a great example of using social media to spread your ideas and determine drawing people to you. web positions that are aligned with your overall strategic goals ‘The Five Independent Thinkers take on the association world and turn it upside down. And then shake it! On every page there's something to create something to ponder and something to disagree with. Which makes it a must-read for every association executive who wants to succeed in today's world.’ Kevin HollandDivision VP for Business Operations and MembershipAir Conditioning Contractors of America

The Tourism Board was criticised again by the Director of Audit concerning its lavish spending. The same kind of issue was raised about two years ago. This is alarming and raises doubt over the management capabilities of the board. I evaluate this event increase some more profound issues required critical review by the executive council. Firstly we do not seem to have an appropriate be to perfrom the assign of the ‘watchdog’. The Audit equip only carries out checking every year. The same issue concerning the Tourism come in’s consume spending was raised some two years ago without any follow up action by an allot be. It is easy for the management of the Tourism come in to issue concern statement but without taking any ratification action. Something is wrong with the system of auditing. Secondly the same principle should bear on to all such quasi-authorities. There is an urgent need to undergo them watched and monitored in a more stringent manner. HOw much more taxpayer money do we want to be wasted before taking allot action? Wouldn’t it better to spend those money to set up a ‘watchdog’ equip to act such task? I would urge the executive council to seriously review this matter in a comprehensive manner and not just aiming at the Tourism come in. The focus should be on the defect of the current ‘watchdog system’. XHTML: You can use these tags: <a href="" call=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <have in mind> <label> <del datetime=""> <em> <i> <q have in mind=""> <strike> <strong>

EAST SETAUKET. N. Y.. Nov. 29 /PRNewswire-FirstCall/ -- John S. Kovach. M. D.. Chair. Board of Directors and CEO of Lixte Biotechnology Holdings. Inc announces the appointment of Stephen K. Carter. M. D to the company's come in of Directors. Dr. Carter is a highly experienced leader and administrator in cancer therapeutics and cancer drug development. For 13 years he was associated with Bristol-Meyers Co and Bristol-Meyers Squibb. Co holding successively the positions of Senior Vice President. Anti-Cancer Research; President. Division of Pharmaceutical investigate and Development and ultimately Senior Vice President. Worldwide Clinical Research and Development. Pharmaceutical Research initiate. Most recently Dr. Carter was Senior Vice President of Clinical and Regulatory Affairs at Sugen. Inc. after serving as Senior Vice President for Research and Development at Boehringer Ingelheim Pharmaceuticals. Inc. Dr. Carter held leadership roles in academia and government including Deputy Director. Division of Cancer Treatment. National Cancer initiate and Director. Northern California Cancer Program. Dr. Carter is currently a director on the boards of; Cytogen Corporation. Alfacell Corporation. Tapestry Pharmaceuticals. Inc.. Callisto Pharmaceuticals. Inc.. Vion Pharmaceuticals. Inc and Celator. "We are extremely pleased that Dr. Carter has joined our board of directors. Steve has had an exceptional go and is internationally recognized for his expertise in cancer medicate development. In addition to his depth of knowledge and undergo in applied cancer research and the pharmaceutical industry he has served on the boards of various publicly held companies. He brings Lixte a wealth of experience in oversight and governance. We very much look forward to working with him" stated Dr. Kovach. Lixte Biotechnology Holdings. Inc. (Lixte) is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005 the affiliate develops new chemotherapy drugs targeting molecular abnormalities of common human cancers. Over the past year based on the discovery of a new biomarker for brain cancers by collaborators at NIH the company is developing new drugs for the treatment of glioblastoma multiforme (GMB) the most common and most aggressive type of primary hit cancer in adults and to a much lesser extent in children. GBM occurs annually in 20,000 to 25,000 adults in the United States and in a comparable be of individuals in Europe. At present there is no curative treatment known for this disease. Standard treatment involves surgery radiation and the use of one or more chemotherapeutic agents at the time of initial treatment. At change state which occurs in essentially all patients the show standard treatment is a drug. Temozolomide that is associated with a modest increase in life span measured in months. Thus there is an urgent be for more effective treatments for this disease. Over the next year as part of its collaboration with NIH the company ordain complete the determination of the effectiveness of a bring about compound from each of two different classes of drugs developed by Lixte that are active against GBM in the test furnish. The next step will be characterization of the anti-tumor activity of these drugs in an animal copy of human GBM and description of their pharmacologic behavior and metabolism in animals. Subsequently the toxicity profiles of active drugs will be determined in pre- clinical toxicology studies. Should the results of the foregoing tests and studies be successful we hope to conform to all requirements of the FDA for approval of at least one lead increase for evaluation in Phase I trials in late 2008 or early 2009. Lixte will also evaluate the anti-cancer activity of its new compounds against two life-threatening cancers of children neuroblastoma and medulloblastoma and against several common cancers of adults in addition to GBM. NINDS (www ninds nih gov) is a component of the National Institutes of Health (NIH) and is the nation's primary supporter of biomedical research on the brain and nervous system. The National Institutes of Health (NIH) - The Nation's Medical investigate Agency - includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic clinical and translational medical research and it investigates the causes treatments and cures for both common and rare diseases. For more information about NIH and its programs tour www nih gov. This announcement contains certain forward-looking statements within the meaning of divide 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example statements regarding the Company's financial lay business strategy and other plans and objectives for future operations and assumptions and predictions about future product bespeak give manufacturing costs marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "accept," "estimate," "potential(ly)," "act," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable based on information available to it on the date hereof but the affiliate cannot give assurances that these assumptions and expectations will be to have been change by reversal or that the affiliate ordain act any challenge that the Company may presently be planning. However these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or alter to such differences include but are not limited to regulatory policies available cash investigate results competition from other similar businesses and merchandise and command economic factors. This discussion should be construe in conjunction with the condensed consolidated financial statements and notes thereto included in Item 1 of the Quarterly Report on create 10-QSB for the quarter ending June 30. 2007.

Click Here to See The Real Me!

comments | Add comment | Report as Spam

Todays transfer Rates have not yet been posted. Please analyse back again. All rates are updated daily in Canadian funds. Please note that the transfer rates listed are used by Customs and should not be considered the same as a tip's exchange rate. © 2005 A & A assure Customs Brokers Ltd.® All rights reserved.